Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014378 | 0.88 | KMT2A (0.46) | HPGDPOLBTSHRMEN1KMT2A | |
| SCHEMBL5012797 | 0.78 | HPGD (0.54) | HPGDALDH1A1TP53MEN1GAA | |
| SCHEMBL5014449 | 0.76 | HPGD (0.58) | HPGDPOLBALDH1A1TSHRTP53 | |
| SCHEMBL14858253 | 0.73 | HPGD (0.62) | HPGDALDH1A1MEN1GAAHTT | |
| SCHEMBL5014405 | 0.73 | GNE (0.55) | HPGDPOLBALDH1A1TP53RECQL | |
| SCHEMBL5338061 | 0.72 | HPGD (0.65) | HPGDALDH1A1TSHRRECQLKDM4E | |
| SCHEMBL15445063 | 0.70 | SIGMAR1 (0.64) | HPGDKDM4E | |
| SCHEMBL939096 | 0.70 | PROKR1 (0.63) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL34463093 | 0.70 | HPGD (0.58) | HPGDPOLBALDH1A1TSHRRECQL | |
| SCHEMBL14872336 | 0.70 | PROKR1 (0.63) | HPGDALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1831231-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065209-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNA2, CHRNB1 | HPGD 1807/4885POLB 4567/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.